Developer docs
API playgroundTry for free, no card

Search company profiles

EvolutionaryScale

Full company profile

uuid00007i9

Namestring
EvolutionaryScale
Legal namestring
EVOLUTIONARYSCALE, PBC
Company typeenum
Private
Founded yearint
2024
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
protein language models, generative protein design, computational drug discovery, biomolecular structure prediction, AI life sciences
Industry5 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Computer Systems Design and Related Services54151
  • Other Computer Related Services541519
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Prepackaged Software7372
  • Biological Products, (No Disgnostic Substances)2836
Product category
AI Computational Biology / Drug Discovery
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1API Access (Commercial)
TypeUsage Based
Description

Paid API access through Forge platform for commercial use of ESM3 models. Tiered pricing based on usage with Industry Model Research Preview available for evaluation.

evolutionaryscale.ai
2Cloud Marketplace Licensing
TypeSubscription Recurring
Description

Pay-as-you-go access through AWS SageMaker for ESMC models (300M, 600M, 6B). Commercial licensing fees for enterprise deployment.

evolutionaryscale.ai
3Non-Commercial API Access
TypeFreemium
Description

Free API access for non-commercial purposes including academic research, non-profit organizations, research institutes, and educational institutions.

evolutionaryscale.ai
4Open Source Models
TypeFreemium
Description

Free open-weight models (ESM3-open 1.4B, ESMC 300M) released under non-commercial licenses to build community adoption and scientific goodwill.

evolutionaryscale.ai
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Infrastructure, Personnel, Operations, Marketing or Sales
Pricing details4 tiers
1Non-Commercial Free Tier
ModelFreemiumBilling cadenceMonthly
Notes

Free API access for universities, non-profit organizations, research institutes, and educational/governmental bodies for non-commercial research purposes.

evolutionaryscale.ai
2Commercial API Access (Forge)
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Pay-per-use commercial licensing through Forge platform for ESM-3, ESMC 300M, ESMC 600M models. Industry Model Research Preview available for evaluation.

evolutionaryscale.ai
3AWS SageMaker Commercial Access
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Pay-as-you-go access to ESMC 300M, 600M, and 6B models through AWS SageMaker marketplace with no minimum inference fees.

evolutionaryscale.ai
4Open Weight Models
ModelFreemiumBilling cadenceMonthly
Notes

ESM3 1.4B open model and ESMC 300M/600M available free under non-commercial license (community license). ESMC 6B available for academic use on Forge and commercial use on AWS.

evolutionaryscale.ai
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1ESM3
Description

A frontier language model for the life sciences that jointly reasons over protein sequence, structure, and function, enabling scientists to understand, imagine, and create proteins.

evolutionaryscale.ai
+4 more records
Core offering1 text field

EvolutionaryScale develops and commercializes frontier AI protein language models for therapeutic and protein engineering applications. Its core products include ESM3, a 98-billion parameter generative model that reasons jointly over protein sequence, structure, and function, and the ESM Cambrian representation learning family. Models are delivered through the Forge API, AWS SageMaker, and NVIDIA BioNemo for commercial pharmaceutical and biotech customers, with free non-commercial access for academic and research institutions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Generated esmGFP, a novel fluorescent protein 58% sequence dissimilar to closest natural protein, representing equivalent of 500+ million years of evolution
+1 more record
Product overview1 text field

EvolutionaryScale offers a suite of AI models and tools for protein biology research. The core products include ESM3 (a generative language model for creating new proteins), ESM Cambrian (a representation learning model family), ESMC (a protein language model for functional analysis), and ESMFold2 (for structure prediction). These are accessible through the Forge API platform and supported by ESM Atlas (a database of 6.8B+ protein annotations) and the Fold web tool. The company rebranded to Biohub.ai in late 2024/early 2025, unifying EvolutionaryScale and Forge under the Biohub platform.

Product and service6 records
1ESM3
CategoryGenerative AI Protein Model
Description

Frontier generative protein language model that simultaneously reasons over sequence, structure, and function of proteins, enabling scientists to understand, imagine, and create proteins for therapeutic, research, and clean-energy applications.

2ESM Cambrian
CategoryProtein Representation Learning Model
Description

Parallel model family to ESM3 focused on protein representation learning rather than generation, available in 300M, 600M, and 6B parameter scales, with state-of-the-art performance across protein understanding tasks.

3ESMC
CategoryProtein Language Model
Description

Protein language model that builds representations capturing fundamental mechanisms of protein structure and function from billions of evolutionary sequences, used for functional analysis, structure prediction, and protein design.

4ESMFold2
CategoryStructure Prediction Model
Description

Model for predicting high-resolution, all-atom 3D structures of biomolecular complexes directly from protein, DNA, and RNA sequences.

5Forge API Platform
CategoryAPI Platform
Description

API platform providing access to ESM3 and ESMC models, with closed-beta and commercial tiers, plus free Industry Model Research Preview for evaluation.

6ESM Atlas
CategoryProtein Knowledge Base
Description

Open database providing functional annotations for over 6.8 billion proteins and 1.1 billion paired high-resolution predicted structures, powered by ESM family models.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-07
Description

CZI acquired EvolutionaryScale as part of restructuring to unify its scientific research entities under Biohub. The acquisition integrates EvolutionaryScale's AI capabilities with CZI's biomedical research mission focused on curing, preventing, and managing diseases through AI-powered scientific research.

Strategic tierMajorTypeTechnology or Integration
Description

ESM3 available on AWS via SageMaker and Bedrock. ESMC models (300M, 600M, 6B) available on AWS Marketplace for commercial deployment. Partnership enables enterprise customers to access models through existing cloud infrastructure.

Strategic tierMajorTypeTechnology or Integration
Description

ESM3 will be available on NVIDIA BioNemo and as an NVIDIA NIM microservice, optimized in collaboration with NVIDIA. Strategic infrastructure partnership for AI model deployment.

Strategic tierMinorTypeOthers
Description

EvolutionaryScale (which raised $142 million) and Amgen are profiled as key companies in Harvard's overview of AI's role in drug discovery.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Offers a generative AI platform for protein engineering used by biotech and pharma teams. Comparable in providing commercial protein-design APIs and targeting the same therapeutic R&D buyer.

TypeDirect peer
Description

Applies large language models trained on protein sequences to design novel functional proteins, including gene editors. Closely aligned with EvolutionaryScale's protein-LM-first approach and open-model philosophy.

TypeDirect peer
Description

Combines generative AI antibody design with a wet-lab validation engine for drug discovery. Closely comparable in applying foundation models to de novo antibody and protein therapeutic design.

TypeBroad incumbent
Description

Established AI drug discovery platform spanning target identification, generative chemistry, and clinical development. Broader scope than EvolutionaryScale but directly competes for pharma AI-platform budgets.

5Isomorphic Labs
TypeDirect peer
Description

Alphabet/DeepMind-owned commercial spin-out developing AI for drug discovery, anchored by AlphaFold for protein structure prediction. Most direct competitor in applying large-scale deep learning to protein biology and therapeutic design.

TypeDirect peer
Description

Developer of generative biology platforms (Chroma) that design novel protein therapeutics from first principles. Directly comparable in offering generative protein design as a service to pharma partners.

TypeBroad incumbent
Description

Public AI-driven drug discovery company using high-throughput biology and machine learning. Overlaps as a competing AI-for-pharma platform with broader wet-lab and pipeline ambitions.

8Iambic Therapeutics
TypeDirect peer
Description

AI-driven drug discovery company combining protein foundation models with physics-based simulation to design small molecules and protein therapeutics. Overlaps in AI-for-protein and AI-for-pharma end markets.

TypeEmerging player
Description

Cloud protein engineering platform combining AI-driven design with high-throughput wet-lab validation. Smaller and earlier stage, but addresses the same protein-design-from-LM end market with a services overlay.

TypeBroad incumbent
Description

Originated the ESM project from which EvolutionaryScale spun out. Continues to release open protein LMs (ESM2, ESMFold) and represents both the academic lineage and a potential open-source competitive ceiling.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EvolutionaryScale

AI Computational Biology / Drug Discoveryevolutionaryscale.ai

EvolutionaryScale firmographics

Firmographics
Name
EvolutionaryScale
Legal name
EVOLUTIONARYSCALE, PBC
Website
https://evolutionaryscale.ai
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

EvolutionaryScale industry classification

Industry
Product category
AI Computational Biology / Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151), Other Computer Related Services (541519)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Protein language models
  • Generative protein design
  • Computational drug discovery
  • Biomolecular structure prediction
  • AI life sciences

Where EvolutionaryScale is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

EvolutionaryScale business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Infrastructure, Personnel, Operations, Marketing or Sales

Revenue model

  1. API Access (Commercial): Paid API access through Forge platform for commercial use of ESM3 models. Tiered pricing based on usage with Industry Model Research Preview available for evaluation.
  2. Cloud Marketplace Licensing: Pay-as-you-go access through AWS SageMaker for ESMC models (300M, 600M, 6B). Commercial licensing fees for enterprise deployment.
  3. Non-Commercial API Access: Free API access for non-commercial purposes including academic research, non-profit organizations, research institutes, and educational institutions.
  4. Open Source Models: Free open-weight models (ESM3-open 1.4B, ESMC 300M) released under non-commercial licenses to build community adoption and scientific goodwill.

Pricing tiers

ModelBillingPrice
FreemiumMonthlyNon-Commercial Free Tier
Usage-basedPay-as-you-goCommercial API Access (Forge)
Usage-basedPay-as-you-goAWS SageMaker Commercial Access
FreemiumMonthlyOpen Weight Models

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

EvolutionaryScale product offering

Product offering

Core offering

EvolutionaryScale develops and commercializes frontier AI protein language models for therapeutic and protein engineering applications. Its core products include ESM3, a 98-billion parameter generative model that reasons jointly over protein sequence, structure, and function, and the ESM Cambrian representation learning family. Models are delivered through the Forge API, AWS SageMaker, and NVIDIA BioNemo for commercial pharmaceutical and biotech customers, with free non-commercial access for academic and research institutions.

Product overview

EvolutionaryScale offers a suite of AI models and tools for protein biology research. The core products include ESM3 (a generative language model for creating new proteins), ESM Cambrian (a representation learning model family), ESMC (a protein language model for functional analysis), and ESMFold2 (for structure prediction). These are accessible through the Forge API platform and supported by ESM Atlas (a database of 6.8B+ protein annotations) and the Fold web tool. The company rebranded to Biohub.ai in late 2024/early 2025, unifying EvolutionaryScale and Forge under the Biohub platform.

Differentiator

Problem solved

Functional benefit

Brands

  • ESM3: A frontier language model for the life sciences that jointly reasons over protein sequence, structure, and function, enabling scientists to understand, imagine, and create proteins.
  • ESM Cambrian
  • ESM Atlas
  • Forge
  • esmGFP

Products and services

  • ESM3 Frontier generative protein language model that simultaneously reasons over sequence, structure, and function of proteins, enabling scientists to understand, imagine, and create proteins for therapeutic, research, and clean-energy applications.
  • ESM Cambrian Parallel model family to ESM3 focused on protein representation learning rather than generation, available in 300M, 600M, and 6B parameter scales, with state-of-the-art performance across protein understanding tasks.
  • ESMC Protein language model that builds representations capturing fundamental mechanisms of protein structure and function from billions of evolutionary sequences, used for functional analysis, structure prediction, and protein design.
  • ESMFold2 Model for predicting high-resolution, all-atom 3D structures of biomolecular complexes directly from protein, DNA, and RNA sequences.
  • Forge API Platform API platform providing access to ESM3 and ESMC models, with closed-beta and commercial tiers, plus free Industry Model Research Preview for evaluation.
  • ESM Atlas Open database providing functional annotations for over 6.8 billion proteins and 1.1 billion paired high-resolution predicted structures, powered by ESM family models.

Quantifiable outcome

  • Generated esmGFP, a novel fluorescent protein 58% sequence dissimilar to closest natural protein, representing equivalent of 500+ million years of evolution
  • +1 more outcomes

Companies that use EvolutionaryScale

Customer profile

Segments3 records

Ideal customer profiles3 records

EvolutionaryScale technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability3 records

Feature6 records

EvolutionaryScale partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, major and minor.

  • Chan Zuckerberg Initiative (CZI) / BiohubcoreStrategic or Co-development Partner · 7 November 2025CZI acquired EvolutionaryScale as part of restructuring to unify its scientific research entities under Biohub. The acquisition integrates EvolutionaryScale's AI capabilities with CZI's biomedical research mission focused on curing, preventing, and managing diseases through AI-powered scientific research.
  • Amazon Web Services (AWS)majorTechnology or IntegrationESM3 available on AWS via SageMaker and Bedrock. ESMC models (300M, 600M, 6B) available on AWS Marketplace for commercial deployment. Partnership enables enterprise customers to access models through existing cloud infrastructure.
  • NVIDIAmajorTechnology or IntegrationESM3 will be available on NVIDIA BioNemo and as an NVIDIA NIM microservice, optimized in collaboration with NVIDIA. Strategic infrastructure partnership for AI model deployment.
  • Harvard (Research Reference)minorOthersEvolutionaryScale (which raised $142 million) and Amgen are profiled as key companies in Harvard's overview of AI's role in drug discovery.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

EvolutionaryScale competitors and assessment

Company assessment

Direct peers

  • Cradle Bio: Offers a generative AI platform for protein engineering used by biotech and pharma teams. Comparable in providing commercial protein-design APIs and targeting the same therapeutic R&D buyer.
  • Profluent Bio: Applies large language models trained on protein sequences to design novel functional proteins, including gene editors. Closely aligned with EvolutionaryScale's protein-LM-first approach and open-model philosophy.
  • Absci: Combines generative AI antibody design with a wet-lab validation engine for drug discovery. Closely comparable in applying foundation models to de novo antibody and protein therapeutic design.
  • Isomorphic Labs: Alphabet/DeepMind-owned commercial spin-out developing AI for drug discovery, anchored by AlphaFold for protein structure prediction. Most direct competitor in applying large-scale deep learning to protein biology and therapeutic design.
  • Generate Biomedicines: Developer of generative biology platforms (Chroma) that design novel protein therapeutics from first principles. Directly comparable in offering generative protein design as a service to pharma partners.
  • Iambic Therapeutics: AI-driven drug discovery company combining protein foundation models with physics-based simulation to design small molecules and protein therapeutics. Overlaps in AI-for-protein and AI-for-pharma end markets.

Broad incumbents

  • Insilico Medicine: Established AI drug discovery platform spanning target identification, generative chemistry, and clinical development. Broader scope than EvolutionaryScale but directly competes for pharma AI-platform budgets.
  • Recursion Pharmaceuticals: Public AI-driven drug discovery company using high-throughput biology and machine learning. Overlaps as a competing AI-for-pharma platform with broader wet-lab and pipeline ambitions.
  • Meta AI (Fundamental AI Research / ESM project): Originated the ESM project from which EvolutionaryScale spun out. Continues to release open protein LMs (ESM2, ESMFold) and represents both the academic lineage and a potential open-source competitive ceiling.

Emerging players

  • Adaptyv Bio: Cloud protein engineering platform combining AI-driven design with high-throughput wet-lab validation. Smaller and earlier stage, but addresses the same protein-design-from-LM end market with a services overlay.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

EvolutionaryScale social profiles

Digital presence

EvolutionaryScale financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EvolutionaryScale leadership team

Management profile

Number of profiles

EvolutionaryScale funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EvolutionaryScale M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EvolutionaryScale

What does EvolutionaryScale do?

EvolutionaryScale develops and commercializes frontier AI protein language models for therapeutic and protein engineering applications. Its core products include ESM3, a 98-billion parameter generative model that reasons jointly over protein sequence, structure, and function, and the ESM Cambrian representation learning family. Models are delivered through the Forge API, AWS SageMaker, and NVIDIA BioNemo for commercial pharmaceutical and biotech customers, with free non-commercial access for academic and research institutions.

Is EvolutionaryScale a public or private company?

EvolutionaryScale is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was EvolutionaryScale founded?

EvolutionaryScale was founded in 2024. It employs 11 to 50 people.

Where is EvolutionaryScale based?

EvolutionaryScale is headquartered in New York, United States, in the North America region.

How does EvolutionaryScale make money?

Four revenue lines are on record. API Access (Commercial) is the primary driver. The others are cloud Marketplace Licensing, non-Commercial API Access and open Source Models.

Who are EvolutionaryScale's main competitors?

Direct peers on record are Cradle Bio, Profluent Bio, Absci, Isomorphic Labs, Generate Biomedicines and Iambic Therapeutics. Broad incumbents are Insilico Medicine, Recursion Pharmaceuticals and Meta AI (Fundamental AI Research / ESM project). Adaptyv Bio is listed as an emerging player.

Does EvolutionaryScale have an API?

Yes. EvolutionaryScale offers API access to ESM3 and ESMC models through Forge (closed Beta), with models available in three sizes (small, medium, large). ESM3-open (1.4B parameters) with weights and source code available on GitHub under non-commercial license. Models are also available on AWS SageMaker and will be available on NVIDIA BioNemo and AWS Bedrock. Developer documentation is at biohub.ai/api-reference.

What industry is EvolutionaryScale in?

EvolutionaryScale's product category is AI Computational Biology / Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LeiphoneAnthropic、Moderna先后引爆舆论场,AI制药到底该奖励什么?Anthropic used Claude to design 14 protein binders with 22.6-35.1% hit rates, while Moderna and Merck's personalized mRNA vaccine met Phase III endpoints. Experts say AI's algorithmic breakthroughs are overshadowed by validation and industrialization challenges, with AI still limited to specific tasks.The Times of IndiaMark Zuckerberg's philanthropic venture unveils AI world model for drug discovery - The Economic TimesBiohub, the philanthropic venture of Meta CEO Mark Zuckerberg and his wife Priscilla Chan, launched on Wednesday a world model of protein biology built on fourth-generation evolutionary scale modeling to accelerate drug discovery. The AI model, designed to understand protein functions by learning from evolutionary protein sequences, was used by researchers to design new protein binders for cancer and immune targets that effectively reactivated immune cells in lab tests. The Chan-Zuckerberg Initiative unified its biomedical research under Biohub in November 2025, including the acquisition of AI-biology startup EvolutionaryScale, with the couple having committed over $7 billion to charity since 2015.GenengnewsBiohub Releases Protein Biology World Model to Address DiseaseBiohub released ESMC, a protein language model trained on 2.8 billion sequences, with ESMFold2 for binder design. Lab-validated binders against five disease targets achieved hit rates of 36–88% for mini-binders and 15–29% for antibody formats. The models are open-source under an MIT license.WtvbamZuckerberg’s philanthropic venture unveils AI world model for drug discoveryBiohub, the philanthropic venture of Meta CEO Mark Zuckerberg and his wife Dr. Priscilla Chan, launched a world model of protein biology built on evolutionary scale modeling to accelerate drug discovery for diseases including cancer and immune conditions. The open-source AI models, developed by researchers who designed protein binders that effectively reactivated immune cells in lab tests, will be available to researchers through Biohub's platform, AWS Bio Discovery, and SandboxAQ. The Chan Zuckerberg Initiative, which acquired AI-biology startup EvolutionaryScale in November 2025, has committed over $7 billion to charity since 2015.SynbiointelAI Protein Design: Every Company Using AI to Engineer Proteins (2026)AI protein design has transitioned from academic research to commercial application, with multiple companies validating functional de novo proteins through wet-lab experiments during 2024-2025. The competitive landscape is organized into foundation model companies (such as EvolutionaryScale), vertically integrated firms (including Absci and Generate Bio), optimization platforms (such as Cradle), and established drug companies (such as Recursion) that are scaling AI across discovery pipelines. The critical strategic question for the industry is whether protein language models will commoditize rapidly like text LLMs, or whether proprietary training data and wet-lab integration will create sustainable competitive advantages.ObserverMark Zuckerberg and Priscilla Chan’s Philanthropy Shuffles Staff Amid A.I. PivotThe Chan Zuckerberg Initiative (CZI) is cutting approximately 70 roles, representing about 8% of its staff, as part of a strategic pivot from social advocacy toward AI-powered scientific research focused on disease cure and prevention. The philanthropy, founded by Meta CEO Mark Zuckerberg and his wife Priscilla Chan in 2015, is redirecting the bulk of its resources—stemming from a pledged $45 billion in Meta shares—toward expanding its Biohub network of AI-powered biology research centers, having recently acquired the team from EvolutionaryScale. The organization, which has distributed over $7 billion in grants, previously eliminated 48 education roles in 2023 as it scaled back DEI programs and various social mission initiatives.Business InsiderMark Zuckerberg says researchers at his philanthropy don't want more lab space or head count: 'They just want GPUs'Mark Zuckerberg and Priscilla Chan announced that their philanthropy, the Chan Zuckerberg Initiative (CZI), is prioritizing GPU computing power over traditional lab expansion to advance its new AI-powered biology mission. CZI is expanding its compute capacity from 1,000 GPUs currently to 10,000 GPUs by 2028, with the organization partnering with EvolutionaryScale through its backed research hub Biohub. The shift represents CZI's move away from its 2015 focus on education and public policy toward what Zuckerberg described as "going all in on AI-powered biology."News-MedicalNew initiative focuses on advancing human disease research through AI and frontier biologyBiohub announced a new initiative combining frontier AI and frontier biology to accelerate disease research, partnering with EvolutionaryScale. The organization will expand its compute capacity tenfold to 10,000 GPUs by 2028 and pursue four scientific grand challenges, including a virtual immune system and new AI models.GenomeWebIn Brief This Week: CZI, Oxford Nanopore Technologies, Metabolon, Bruker, MoreThe Chan Zuckerberg Initiative acquired EvolutionaryScale, a company developing artificial intelligence algorithms for life sciences, as part of a broader organizational restructuring. The deal brings CZI Science and the Chan Zuckerberg Biohub network together under a new unified entity called Biohub, which will serve as the primary philanthropic vehicle for Mark Zuckerberg and Priscilla Chan. EvolutionaryScale Cofounder Alex Rives, a former Meta employee, will become head of science at the new Biohub entity, though financial terms were not disclosed.